BHVN

Biohaven Ltd.'s stock price has experienced significant fluctuations and a general decline over the past six months, declining by 57.43% from May 5, 2025, to May 1, 2026. Key events include reporting first-quarter 2026 financial results with a narrower net loss, completing enrollment in a Phase 2 obesity study for Taldefgrobep Alfa, releasing fourth-quarter and full-year 2025 financial results with a net loss, highlighting portfolio progress at the 44th Annual J.P. Morgan Healthcare Conference, experiencing an 11.8% stock drop after BHV-7000 failed to meet the primary endpoint in a Phase 2 trial for major depressive disorder, and the FDA rejecting Vyglxia (troriluzole).